Riociguat-[d3]
A stable labelled compound of Riociguat. Riociguat (BAY 63-2521; BAY 632521) is a novel drug that is currently in clinical development by Bayer. At the moment Phase III clinical trials investigate the use of riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of a novel class of sGC stimulators.
| Supplier | BOC Sciences |
|---|---|
| Product # | BLP-004143 |
| Pricing | Inquire |
| Cas | 1304478-72-5 |
| Molecular Weight | 425.43 |
| Molecular Formula | C20H16D3FN8O2 |
| Canonical SMILES | CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC |